Zynerba Pharmaceuticals Reports Second Quarter 2016 Financial …

Jim Fickenscher will assume role as Chief Financial Officer, VP, Corporate Development

Dr. Nancy Tich appointed VP, Clinical, in a newly created position

DEVON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) — Zynerba Pharmaceuticals, Inc. (ZYNE), a clinical-stage specialty pharmaceutical company dedicated to the development of innovative transdermal synthetic cannabinoid treatments, today reported financial results for the second quarter ended June 30, 2016 and changes to the Company’s executive management team.

Zynerba announced that Jim Fickenscher will replace Richard Baron as Chief Financial Officer, Vice President, Corporate Development, effective September 13, 2016. Mr. Fickenscher joins Zynerba with 28 years of experience in the pharmaceutical industry. Most recently, he was Senior Vice President, Chief Financial Officer at Antares Pharma, a commercial pharmaceutical company focused on self-administered parenteral products. He has also

... read more at: http://finance.yahoo.com/news/zynerba-pharmaceuticals-reports-second-quarter-111500755.html